牛牛AI助手已提取核心信息维立志博2025年上半年亏损由去年同期的1.80亿元人民币减少7.8%至1.66亿元。期内研发成本增加56.9%至1.32亿元,主要由于LBL-024生物制品许可申请筹备工作相关的CMC开发里程碑开支增加,以及加快LBL-024及LBL-034的患者入组和临床进展。行政开支减少39%至3,583万元,主要由于2024年上半年授出的股份奖励即时归属并确认相关开支,但部分被...
Source Link牛牛AI助手已提取核心信息维立志博2025年上半年亏损由去年同期的1.80亿元人民币减少7.8%至1.66亿元。期内研发成本增加56.9%至1.32亿元,主要由于LBL-024生物制品许可申请筹备工作相关的CMC开发里程碑开支增加,以及加快LBL-024及LBL-034的患者入组和临床进展。行政开支减少39%至3,583万元,主要由于2024年上半年授出的股份奖励即时归属并确认相关开支,但部分被...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.